281 related articles for article (PubMed ID: 22228563)
1. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
2. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy.
Noblitt LW; Bangari DS; Shukla S; Mohammed S; Mittal SK
Cancer Gene Ther; 2005 Jan; 12(1):46-53. PubMed ID: 15486559
[TBL] [Abstract][Full Text] [Related]
3. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
4. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
5. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Wykosky J; Gibo DM; Debinski W
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma.
Li X; Wang L; Gu JW; Li B; Liu WP; Wang YG; Zhang X; Zhen HN; Fei Z
Tumour Biol; 2010 Oct; 31(5):477-88. PubMed ID: 20571968
[TBL] [Abstract][Full Text] [Related]
7. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
8. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
9. Bidirectional signalling between EphA2 and ephrinA1 increases tubular cell attachment, laminin secretion and modulates erythropoietin expression after renal hypoxic injury.
Rodriguez S; Rudloff S; Koenig KF; Karthik S; Hoogewijs D; Huynh-Do U
Pflugers Arch; 2016 Aug; 468(8):1433-48. PubMed ID: 27228995
[TBL] [Abstract][Full Text] [Related]
10. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.
Yang XY; Zhu WJ; Jiang H
Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484
[TBL] [Abstract][Full Text] [Related]
11. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin-Producing Hepatoma Receptor Tyrosine Kinase A2 Modulation Associates with Protective Effect of Prone Position in Ventilator-induced Lung Injury.
Park BH; Shin MH; Douglas IS; Chung KS; Song JH; Kim SY; Kim EY; Jung JY; Kang YA; Chang J; Kim YS; Park MS
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):519-529. PubMed ID: 29216437
[TBL] [Abstract][Full Text] [Related]
13. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
14. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland.
Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z
J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804
[TBL] [Abstract][Full Text] [Related]
15. Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level.
Mo J; Zhao X; Dong X; Liu T; Zhao N; Zhang D; Wang W; Zhang Y; Sun B
Cell Oncol (Dordr); 2020 Aug; 43(4):655-667. PubMed ID: 32291572
[TBL] [Abstract][Full Text] [Related]
16. EphrinA1-Fc Attenuates Ventricular Remodeling and Dysfunction in Chronically Nonreperfused WT but not EphA2-R-M mice.
Whitehurst KS; Chan VA; Estes HK; Valsaraj S; Kent S; Sharma UM; Chase RC; Bhuiyan M; Virag JAI
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823610
[TBL] [Abstract][Full Text] [Related]
17. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites.
Tognolini M; Giorgio C; Hassan Mohamed I; Barocelli E; Calani L; Reynaud E; Dangles O; Borges G; Crozier A; Brighenti F; Del Rio D
J Agric Food Chem; 2012 Sep; 60(36):8877-84. PubMed ID: 22409255
[TBL] [Abstract][Full Text] [Related]
18. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
[TBL] [Abstract][Full Text] [Related]
19. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase.
Parri M; Buricchi F; Taddei ML; Giannoni E; Raugei G; Ramponi G; Chiarugi P
J Biol Chem; 2005 Oct; 280(40):34008-18. PubMed ID: 16051609
[TBL] [Abstract][Full Text] [Related]
20. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]